New Review Article Looks at Collaborations among Researchers, Patient Groups, and Industry

Posted by • May 10th, 2017

A growing approach to developing new treatments is a partnership among researchers, patient groups, and industry. A new article in the Clinical Trials review series gives three examples of such collaborations.

“In an era of reduced federal funding for basic and preclinical research and drug development (coupled with a higher bar for regulatory compliance),” the authors write, “the challenges that many medical professionals are routinely faced with continue to remain daunting and require new and collaborative approaches for ongoing success.” This article explains how such collaborations have helped to bridge the preclinical phase to early human research trials.

In the article, the authors describe three examples — in cystic fibrosis, multiple myeloma, and type 1 diabetes — when academic institutions, industry partners, federal agencies, and disease-focused foundations shared relevant information. “In each of the cited cases,” write the authors, “none of the major advances could have occurred in a timely manner if the partners had worked independently.”

The Changing Face of Clinical Trials series is a collection of review articles that examine the current challenges in the design, performance, and interpretation of clinical trials. Read more articles in the series here.

Leave a Reply

The Now@NEJM blog is a forum for medical professionals to discuss articles published in NEJM. Our bloggers cannot respond to requests for personal medical advice, and recommend patients discuss health issues with their individual physicians.

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.

Submitting a comment indicates you have read and agreed to the Terms and Conditions.